Pancreatic Cancer Research

ResearcherSt. ClaraspitalNo recent work listed

Dieter Koeberle

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2742-0115; OpenAlex author ID A5087142746. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 3

  1. Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients? Co-author DOI 10.3390/cancers15174398↗
  2. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results r… Last author DOI 10.1097/mpa.0b013e318291fbc5↗
  3. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Last author DOI 10.1159/000330769↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sara De Dosso · 2 shared papers, 2011–2023 · strength 0.19
  2. Saskia Hussung · 1 shared paper, 2023 · strength 0.16
  3. Stefania Rizzo · 1 shared paper, 2023 · strength 0.16
  4. Marco Cefalì · 1 shared paper, 2023 · strength 0.16
  5. Filippo Del Grande · 1 shared paper, 2023 · strength 0.16
  6. Ralph Fritsch · 1 shared paper, 2023 · strength 0.16
  7. Mathias Worni · 1 shared paper, 2013 · strength 0.04
  8. Beat Gloor · 1 shared paper, 2013 · strength 0.04
  9. Rebekah Ruth White · 1 shared paper, 2013 · strength 0.04
  10. Piercarlo Saletti · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.